Has Keyla Davila Marcano received payments from drug or device companies?

Yes. Drug and device makers reported $3,013 in general payments to Keyla Davila Marcano across 82 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Keyla Davila Marcano did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Keyla Davila Marcano come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Keyla Davila Marcano

Nephrology · Manati, PRNPI 1699177014

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 58.7% of the total.

$3,013in general payments, 2019–2025

Across 82 payments — averaging $36.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
Nxstage Medical, Inc.$308
Calliditas Therapeutics US Inc.$262
GSK$128
Boehringer Ingelheim$115
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
plus $330 from 7 others

What the payments were for

Food & beverage$2,84694%
Education$1676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	57	$1,769
Nxstage Medical, Inc.	2	$308
Calliditas Therapeutics US Inc.	6	$262
GSK	2	$128
Boehringer Ingelheim	4	$115
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$100
Mallinckrodt Enterprises LLC	1	$100
Vifor Pharma, Inc.	3	$92
ANI Pharmaceuticals, Inc.	2	$51
Johnson & Johnson	1	$33
Sanofi	1	$20
Eli Lilly Export S.A. Puerto Rico Branch	1	$19
Scpharmaceuticals Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,013 in reported general payments places this provider in the 70th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$34,484

Medicare patients

Services billed

281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FarxigaDapagliflozin Propanediol	433	$417,105
LokelmaSodium Zirconium Cyclosilicate	188	$124,633
JardianceEmpagliflozin	53	$57,787
RetacritEpoetin Alfa-Epbx	37	$39,509
Lanthanum Carbonate	35	$22,720
OzempicSemaglutide	23	$22,687
TradjentaLinagliptin	22	$20,816
Calcium Acetate	133	$16,815
Sevelamer Carbonate	90	$14,254
Candesartan Cilexetil	18	$2,957
SynthroidLevothyroxine Sodium	40	$2,790
Allopurinol	162	$2,464
Gentamicin Sulfate	36	$2,068
Losartan Potassium	152	$1,857
Cinacalcet Hcl	23	$1,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga, Lokelma	$1,769	$541,738621 claims
Boehringer IngelheimJardiance, Tradjenta	$115	$78,60375 claims
ANI Pharmaceuticals, Inc.Valsartan	$51	$93125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Manati

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →